Daniel P. Petrylak, MD, director, Prostate and Genitourinary Cancer Program, co-director, Signal Transduction Research Program, at the Smilow Cancer Center at Yale-New Haven, describes two novel bone targeted therapies as treatments for men with metastatic castration-resistant prostate cancer.
For more resources and information regarding targeted therapies in cancer: targetedhc.com/
- Dr. Daniel Petrylak Discusses Novel Bone Targeted Therapies in Prostate Cancer ( Download)
- Dr. Daniel Petrylak Discusses Chemotherapy in Prostate Cancer ( Download)
- Dr. Petrylak Discusses PSMA-Directed Therapies in Prostate Cancer ( Download)
- Dr. Daniel Petrylak Describes the Clinical Investigation of PROSTVAC in Prostate Cancer ( Download)
- Dr. Petrylak Discusses Custirsen as a Potential Treatment for Prostate Cancer ( Download)
- Optimal Time for Prostate Cancer Bone-Targeted Therapy ( Download)
- Genetic Testing and Prostate Cancer ( Download)
- Dr. Daniel Petrylak on Biomarker Discovery in Advanced Prostate Cancer ( Download)
- Dr. Petrylak on Imaging Approaches in Prostate Cancer ( Download)
- Dr. Petrylak on PSMA ADC for Patients with mCRPC ( Download)
- Factors Impacting Treatment Approach in Advanced Prostate Cancer ( Download)
- Novel Biomarker-Guided Treatment: PSMA, PAR, HDACs, etc. ( Download)
- Dr. Daniel Petrylak Explains the Correlation Between Immune Response to Sipuleucel-T and Survival ( Download)
- Dr. Petrylak on the Recent Developments in Prostate Cancer ( Download)
- Bone-Targeted Therapy for Prostate Cancer ( Download)
